Frankfurt - Delayed Quote • EUR
Vericel Corporation (ATQP.F)
At close: April 25 at 8:01 AM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.03 | 0.24 | 0.07 | 0.48 |
| Low Estimate | -0.06 | 0.19 | -0.02 | 0.23 |
| High Estimate | 0.01 | 0.31 | 0.11 | 0.61 |
| Year Ago EPS | 0.08 | 0.25 | 0.06 | 0.07 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 6 | 7 |
| Avg. Estimate | 38.07M | 57.54M | 169.84M | 210.68M |
| Low Estimate | 35.5M | 54.68M | 168.9M | 196.5M |
| High Estimate | 41.6M | 60M | 170.8M | 239.25M |
| Year Ago Sales | 32.26M | 45.23M | 124.18M | 169.84M |
| Sales Growth (year/est) | 18.00% | 27.20% | 36.80% | 24.00% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | -0.02 | 0.2 | -0.04 | -0.08 |
| EPS Actual | 0.08 | 0.25 | -0.07 | -0.08 |
| Difference | 0.1 | 0.05 | -0.03 | 0 |
| Surprise % | 500.00% | 25.00% | -75.00% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | -0.03 | 0.24 | 0.07 | 0.48 |
| 7 Days Ago | -0.02 | 0.25 | 0.07 | 0.44 |
| 30 Days Ago | -0.02 | 0.24 | 0.08 | 0.45 |
| 60 Days Ago | -0.02 | 0.22 | 0.05 | 0.41 |
| 90 Days Ago | -0.02 | 0.22 | 0.05 | 0.41 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ATQP.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -137.50% | -- | -- | 2.60% |
| Next Qtr. | -4.00% | -- | -- | 13.40% |
| Current Year | 16.70% | -- | -- | 5.20% |
| Next Year | 585.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 3/26/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/1/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Upgrade | Truist Securities: Hold to Buy | 1/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/16/2024 |
| Maintains | Truist Securities: Hold to Hold | 11/9/2023 |
Related Tickers
GHDN.MU Brainstorm Cell Therapeutics Inc
0.5040
0.00%
GHDN.SG Brainstorm Cell Therapeutics Inc
0.4795
-1.34%
GLSI Greenwich LifeSciences, Inc.
12.34
-2.22%
BIOR Biora Therapeutics, Inc.
0.6070
-2.08%
BLUE bluebird bio, Inc.
0.9125
-1.13%
IOVA Iovance Biotherapeutics, Inc.
11.54
-1.45%
VERU Veru Inc.
1.2100
-8.33%